In this meta-analysis, the acute adverse effect profile of therapeutic single-dose psilocybin appeared to be tolerable and resolved within 48 hours. However, future studies need to more actively evaluate the appropriate management of adverse effects.

Cultural attitudes toward psychedelics are evolving due to promising research about their potential as mental health treatments. Without legal access to match the growing demand for these substances, consumers seek access through an unregulated underground market and may expose themselves to harm. Dispensaries offer a potential solution to this problem.

By the standard measures of drug safety, psychedelics are less dangerous than caffeine.  So, the risks must lie elsewhere.

As psychedelics are becoming increasingly available and research into their use in medicine advances, inclusion of relevant material in academic training programs will be essential to prepare future professionals to effectively educate and counsel patients.

Increasing psychological flexibility may be an important putative mechanism of change in psilocybin-assisted therapy for MDD and potentially, other mental health conditions.

In this narrative review, we focus on the evidence base for the effects of psilocybin on adult hippocampal neurogenesis and microglial form and function; which may suggest that psilocybin has the potential to modulate multiple mechanisms of action, and may have implications in altering the progression from major depression to dementia in those at risk.

Together, these findings provide a novel perspective on meditation and psychedelics that may reveal potential novel brain markers for positive synergistic effects between mindfulness practices and psilocybin.

This study shows a significant reduction in cluster attack frequency in a repeat round of pulse psilocybin administration and suggests that prior response may not predict the effect of repeated treatment.

A psychosocial measure of Communitas emerged as a predictor in older adults (OA), suggesting that the relational components in psychedelic group settings may hold particular value for OA.

For mothers with prenatal depression, a single low dose of esketamine after childbirth decreases major depressive episodes at 42 days post partum by about three quarters.

Conclusions Depression is common among individuals seeking CBMPs to treat PTSD and is associated with greater symptom severity and poorer quality of life. Effectiveness of CBMPs for treating PTSD does not appear to be impaired in people with comorbid depression.

We argue that decriminalisation offers a feasible first step towards reducing the harm of drug control which would not increase drug-related harm.

Participants often turned to psilocybin after conventional treatments had failed. Long diagnosis times and insufficient care from the health sector calls for systemic change; - Experiences with, and approaches to psilocybin were diverse, with most reporting improved quality of life and reduced symptoms, though this was not without challenges.

The idea for Music Centered Psychedelic Integration (MCPI) came about through the slow accumulation of insights and practical ideas based on our clinical training and practice from 2017 up to the present.

A new bill approved this week will allow Utah doctors to prescribe MDMA and psilocybin for their adult mental health patients. That makes Utah the first state in the US to authorize the use of psychedelics as a medical treatment. 

Our findings suggest that perceptions of early attachment experiences may be relevant to psychedelic phenomenology. However, subjective experiences associated with naturalistic psychedelic use do not typically attenuate links between a perceived insecure attachment history and attachment insecurity at present.

These findings are important, as they may indicate that childhood trauma exposure does not pose the same risk for a poor treatment response to ayahuasca, as it predicts in other forms of intervention.

These findings suggest that a single administration of psilocybin is safe with regard to acute psychological and physical harm in healthy participants in a controlled research setting.

Among a comprehensive set of acute experiences related to psilocybin, so-called “mystical experience” and “ego dissolution” were unique in mediating the effect of treatment condition on depressive response with high specificity. Higher reported levels of mystical experience, emotional breakthrough, and intense responses to music-listening were furthermore associated with greater antidepressant response.

Psychedelic-assisted therapy teams may benefit from including spiritual health practitioners. In order to ensure rigorous standards and quality care, further efforts to delineate the roles and necessary qualifications and training of spiritual health clinicians for psychedelic-assisted therapy are needed.